Valneva’s (VALN) “Buy” Rating Reaffirmed at HC Wainwright

Valneva (NASDAQ:VALN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s price objective suggests a potential upside of 242.86% from the stock’s current price.

Valneva Stock Performance

Valneva stock opened at $5.25 on Friday. Valneva has a 52-week low of $3.62 and a 52-week high of $9.50. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock has a fifty day moving average price of $4.32 and a two-hundred day moving average price of $5.72. The firm has a market capitalization of $426.62 million, a P/E ratio of -40.38 and a beta of 1.93.

Institutional Trading of Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA bought a new position in Valneva SE (NASDAQ:VALN) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 19,244 shares of the company’s stock, valued at approximately $84,000. Institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.